ANZUP Cancer Trials Group

New three-year strategy: a plan to support growth towards ANZUP's vision of living life without fear of cancer

Led by the ANZUP Board of Directors and developed through broad consultation with the ANZUP leadership team, employees, Scientific Advisory Committee, subcommittees, membership, Consumer Advisory Panel and other stakeholders, ANZUP proudly launched the new ANZUP Strategy 2025-2028.

Implemented from April 1, the strategy will serve as ANZUP’s plan to deliver on its mission to improve the lives of people affected by bladder, kidney, testicular, penile and prostate cancers, and towards the vision of ‘living life without fear of cancer’. Guided by the values of commitment, collaboration, integrity, respect and agility, ANZUP will focus activities within four strategic pillars: Cancer Research, Reach and Relevance, Capacity Building and Sustainability, and People and Partnerships, with the aim of supporting sustainable growth across ANZUP’s cancer research portfolio.

ANZUP would like to thank everyone who contributed to the development of the plan, in particular the ANZUP Consumer Advisory Panel for providing valuable advice to the Board of Directors on ANZUP’s vision and commitment to following through and achieving its goals. Read about the strategy on the ANZUP website.

#ANZUP25 ASM

The ANZUP 2025 Annual Scientific Meeting was held from 20-22 July 2025 at the Hyatt Regency in Sydney, led by co-convenors Carole Harris and Laurence Krieger. The ASM theme, ‘Listen, Reflect, Connect’, provided a platform to discuss and present the latest updates in genitourinary (GU) cancer treatment, research and supportive care, and to learn more about existing and planned ANZUP trials. The ASM attracted 480 attendees.

Over the three days, delegates had the chance to listen, reflect and connect with international experts, multidisciplinary national leaders, up-and-coming ANZUP stars and consumers committed to clinical and translational research, diagnosis, treatment and management of GU cancers. The collaborative and inclusive spirit that defines ANZUP was evident throughout a program designed for a multidisciplinary audience across all areas of GU cancer care. ANZUP’s patient-centred approach and commitment to diversity, equity and inclusion was particularly evident throughout the program and celebrated by many who attended.

The event featured a wide range of engaging sessions including The Perfect Pitch, the ever-popular MDT Masterclass, the Translational and Supportive Care breakfast series, the always well-attended Nurses Symposium and for the first time, a Study Coordinators session. This session covered a wide range of topics including running theranostics trials, patient reported outcomes, and teletrials. Across the program there were insightful plenary discussions, the essential ANZUP Trials in Action session, lively debates and dynamic poster presentations. ANZUP gratefully acknowledges the valuable contributions of the Consumer Advisory Panel whose active involvement played a key role in the program’s success.

The ASM generated significant interest and participation on social media with over one million #ANZUP25 impressions and close to 300 X posts.

You can watch videos from the ASM on the ANZUP YouTube channel.

Thankyous

Many thanks to the wonderful International Faculty: Roger Li, Tian Zhang, Alison Tree, Marniza Saad, Bishal Gyawali, Emily Grist and Bertrand Tombal, whose talks were both inspirational and informative.

Thanks to the hardworking and dedicated convening committee led by Carole Harris and Laurence Krieger who did an exceptional job engaging the membership. Thanks also to the 2025 sponsors, without whom ANZUP could not have hosted such a fantastic and memorable meeting.

ANZUP thanks every speaker, sponsor, chair, delegate, consumer, participant, committee member and organiser for their valuable contribution to the success of #ANZUP25.

#ANZUP26 ASM

ANZUP’s 2026 ASM is being held in Adelaide from 28-30 June with the convening committee, ably led by Lisa Butler and Craig Gedye. Hear from Lisa and Craig on the ANZUP YouTube channel.

Recent Highlights

ASCO 2025 Annual Meeting
At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago in June 2025, ANZUP proudly showcased the exciting outcomes from globally significant studies across four oral presentations and four posters. It was the largest ANZUP presence ever featured on the main stage and a testament to the hard work ANZUP’s investigators are doing to improve the lives of people impacted by Below the Belt cancers. Read more in the Research Highlights section of the ANZUP website:

ENZA-p Predictive and prognostic value of baseline PSMA-PET total tumor volume (TTV) and SUVmean within a randomised phase 2 trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901)  – Prof Louise Emmett (oral presentation)

BCG+MM Mitomycin plus (BCG), as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial (BC+MM ANZUP 1301) – Professor Dickon Hayne (oral presentation)

EVOLUTION 177 Lu-PSMA-617 with ipilimumab and nivolumab in metastatic castration-resistant prostate cancer (mCRPC): an investigator-initiated phase 2 trial – Prof Shahneen Sandhu (oral presentation)

TheraP Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving 177Lu-PSMA-617 or cabazitaxel: an exploratory post-hoc analysis of a randomized phase II trial – Dr Asli Munzur (oral presentation)

PCR MIB Pembrolizumab (pembro) with chemoradiotherapy (CRT) as treatment for muscle-invasive bladder cancer (MIBC): Long-term follow up of secondary endpoints of efficacy including overall survival of the PCR-MIB phase II clinical trial (ANZUP 1502) – Prof Andrew Weickhardt (poster presentation)

ENZAMET

• • 8-year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ANZUP 1304)  – Dr Alison Zhang (poster presentation)
  • Prognostic value of PSMA-PET against CHAARTED criteria in an ENZAMET sub-cohort  – Prof Louise Emmet (poster presentation)
  • Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304)  – Prof Lisa Horvath (poster presentation)

ANZUP 2025 Annual Report

The ANZUP 2025 Annual Report was released in July and is a powerful reflection of the impact ANZUP has made in advancing cancer research and care. The report showcases the tireless commitment of ANZUP’s members and supporters, and the wider ANZUP community, to improving outcomes for genitourinary cancer patients. The report is more than numbers and updates; it is a reflection of what we’ve achieved together. Thank you to ANZUP’s members, partners, consumers and supporters for continuing to help ANZUP deliver on its mission to improve the lives of people affected by bladder, kidney, testicular, penile and prostate cancers. Read the ANZUP Annual Report 2024-2025.

Other News

Idea Generation Workshops
ANZUP’s Idea Generation Workshops (IGWs) are where the seeds of many ANZUP clinical trials are first sown. They are important in growing and fostering a pipeline of innovative ideas to be considered and prioritised, with support from ANZUP, moving forward. The workshops are held throughout the year, there are two remaining in 2025, the inaugural New Zealand IGW on Friday 12 September and the Bladder Urothelial Penile (BUP) workshop on Friday 7 November. Find out more information on the ANZUP website.

Symposia
The second half of the calendar is looking to be equally busy. ANZUP is holding several member educational events, including the 2025 Asia-Pacific Advanced Prostate Cancer Consensus Satellite Symposium (APAC APCC) in Singapore on Wednesday 3 September and the Best of GU Evening Symposium on Wednesday 12 November in Adelaide.

ANZUP Trial Portfolio
ANZUP’s trial portfolio continues to grow. There are currently five ANZUP-led trials and one co-badged trial in recruitment, 17 in follow-up, and many in development. Read more about the trials on the ANZUP website.